Robert Herring
About
Robert Herring is a scholar working on Epidemiology, Hepatology and Surgery.
According to data from OpenAlex, Robert Herring has authored 23 papers receiving a total of 522 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 11 papers in Hepatology and 3 papers in Surgery. Recurrent topics in Robert Herring's work include Liver Disease Diagnosis and Treatment (13 papers), Hepatitis C virus research (10 papers) and Hepatitis B Virus Studies (5 papers). Robert Herring is often cited by papers focused on Liver Disease Diagnosis and Treatment (13 papers), Hepatitis C virus research (10 papers) and Hepatitis B Virus Studies (5 papers). Robert Herring collaborates with scholars based in United States, Canada and United Kingdom. Robert Herring's co-authors include Tarek Hassanein, Zeid Kayali, M. Rodríguez‐Torres, Robert P. Myers, Mazen Noureddin, Rohit Loomba, Heidi Kabler, Clare A. Balendran, Anita Kohli and Mette Skalshøi Kjær and has published in prestigious journals such as Gastroenterology, Hepatology and Clinical Infectious Diseases.
In The Last Decade
Robert Herring
23 papers receiving 506 citations
Hit Papers
Peers
Robert Herring
Abhishek Chauhan United Kingdom
Barbara Rosado Austria
Jessica Lam United States
Masao Shinohara Japan
Masaki Kawamoto Japan
Gilles Le Naour France
Yanhui Wu China
Wenlong Wang China
Cordelia Ziraldo United States
Citations per year, relative to Robert Herring Robert Herring (= 1×)
peers
Abhishek Chauhan
Countries citing papers authored by Robert Herring
Since
Specialization
Citations
This map shows the geographic impact of Robert Herring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Herring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Herring more than expected).
Fields of papers citing papers by Robert Herring
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Robert Herring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Herring. The network helps show where Robert Herring may publish in the future.
Co-authorship network of co-authors of Robert Herring
This figure shows the co-authorship network connecting the top 25 collaborators of Robert Herring. A scholar is included among the top collaborators of Robert Herring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Herring. Robert Herring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Alkhouri, Naim, Robert Herring, Heidi Kabler, et al.. (2022). Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. Journal of Hepatology. 77(3). 607–618.
2.
Newsome, Philip N., Melissa Palmer, Bradley Freilich, et al.. (2020). Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study. Journal of Hepatology. 73(2). 231–240.
3.
Lawitz, Eric, Edward Gane, Peter Ruane, et al.. (2019). SAT-352-A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis. Journal of Hepatology. 70(1). e794–e794.
4.
Newsome, Philip N., Melissa Palmer, Bradley Freilich, et al.. (2019). LBP-24-Safety, tolerability and efficacy of volixibat, an apical sodium-dependent bile acid transporter inhibitor, in adults with nonalcoholic steatohepatitis: 24-week interim analysis results from a phase 2 study. Journal of Hepatology. 70(1). e152–e153.
5.
Lawitz, Eric, Robert Herring, Ziad Younes, et al.. (2018). Proof of concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in NASH. Journal of Hepatology. 68. S57–S57.
6.
Lawitz, Eric, Robert Herring, Ziad Younes, et al.. (2018). Su1522 - Proof of Concept Study of an Apoptosis-Signal Regulating Kinase (ASK-1) Inhibitor (Selonsertib) in Combination with an Acetyl-Coa Carboxylase Inhibitor (GS-0976) or a Farnesoid X Receptor (FXR) Agonist (GS-9674) in NASH. Gastroenterology. 154(6). S–1166.
7.
Harrison, Stephen A., Mazen Noureddin, Robert Herring, et al.. (2018). Su1521 - Preliminary Efficacy and Safety of Acetyl-Coa Carboxylase (ACC) Inhibitor GS-0976 in Patents with Compensated Cirrhosis due to NASH. Gastroenterology. 154(6). S–1166.
8.
Harrison, S., Mazen Noureddin, Robert Herring, et al.. (2018). Preliminary efficacy and safety of acetyl-CoA carboxylase inhibitor GS-0976 in patients with compensated cirrhosis due to NASH. Journal of Hepatology. 68. S583–S583.
9.
Lawitz, Eric, E DeJesus, Eric M. Yoshida, et al.. (2015). LP04 : A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2. Journal of Hepatology. 62. S264–S265.
10.
Hézode, Christophe, Robert Herring, Paul J. Pockros, et al.. (2015). P0888 : Effect of baseline factors on response to the fixed-dose combination of daclatasvir (DCV), asunaprevir (ASV) and beclabuvir (BCV), with or without ribavirin (RBV), in patients with HCV genotype 1 infection and cirrhosis. Journal of Hepatology. 62. S676–S676.
11.
Thom, Betsy, Susanne MacGregor, Christine Godfrey, et al.. (2013). The Alcohol Improvement Programme: Evaluation of an Initiative to Address Alcohol-Related Health Harm in England. Alcohol and Alcoholism. 48(5). 585–591.
12.
Wedemeyer, Heiner, Donald M. Jensen, Robert Herring, et al.. (2013). Propel: A Randomized Trial of Mericitabine Plus Peginterferon Alpha-2a/Ribavirin Therapy in Treatment-NaïVe HCV Genotype 1/4 Patients. Hepatology. 58(2). 524–537.
13.
Nelson, David R., Stefan Zeuzem, Pietro Andreoné, et al.. (2012). Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients( ). Annals of Hepatology. 11(1). 15–31.
14.
Sulkowski, Mark, M. Rodríguez‐Torres, E. Läwitz, et al.. (2012). 1421 HIGH SUSTAINED VIROLOGIC RESPONSE RATE IN TREATMENT-NAIVE HCV GENOTYPE 1A AND 1B PATIENTS TREATED FOR 12 WEEKS WITH AN INTERFERON-FREE ALL-ORAL QUAD REGIMEN: INTERIM RESULTS. Journal of Hepatology. 56. S560–S560.
15.
Wedemeyer, Heiner, Dorte Møller Jensen, Robert Herring, et al.. (2012). 1213 EFFICACY AND SAFETY OF MERICITABINE (MCB) IN COMBINATION WITH PEG-IFNa-2A/RBV IN G1/4 TREATMENT NAIVE HCV PATIENTS: FINAL ANALYSIS FROM THE PROPEL STUDY. Journal of Hepatology. 56. S481–S482.
16.
Zeuzem, Stefan, David R. Nelson, Pietro Andreoné, et al.. (2010). 778 PHASE IIB STUDY OF BALAPIRAVIR (RG1626; NUCLEOSIDE ANALOGUE INHIBITOR OF HCV POLYMERASE) PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOR CHC GENOTYPE 1: FINAL RESULTS. Journal of Hepatology. 52. S302–S303.
17.
Herring, Robert, et al.. (2009). Rhabdomyolysis caused by an interaction of simvastatin and fusidic acid. BMJ Case Reports. 2009. bcr0320091722–bcr0320091722.
18.
Gaglio, Paul J., M. Rodríguez‐Torres, Robert Herring, et al.. (2004). Racial Differences in Response Rates to Consensus Interferon in HCV Infected Patients Naive to Previous Therapy. Journal of Clinical Gastroenterology. 38(7). 599–604.
19.
Herring, Robert, et al.. (1981). Simulation experiments to compare the signal detection properties of DFT and MEM spectra. IEEE Transactions on Acoustics Speech and Signal Processing. 29(5). 1084–1089.
20.
Herring, Robert. (1980). The cause of line splitting in Burg maximum-entropy spectral analysis. IEEE Transactions on Acoustics Speech and Signal Processing. 28(6). 692–701.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Abhishek Chauhan Breakdown of academic impact, for papers by Barbara Rosado Breakdown of academic impact, for papers by Jessica Lam Breakdown of academic impact, for papers by Masao Shinohara Breakdown of academic impact, for papers by Masaki Kawamoto Breakdown of academic impact, for papers by Gilles Le Naour Breakdown of academic impact, for papers by Yanhui Wu Breakdown of academic impact, for papers by Wenlong Wang Breakdown of academic impact, for papers by Cordelia Ziraldo